Addressing key challenges, trends and strategies in contamination control
Discover how to keep up with regulatory changes and maintain the utmost efficiency during production and testing.
The pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods, revisions being made to regulations in the industry, enhanced knowledge of the human microbiome, and novel testing methods, this industry is expanding. In fact, the value of the rapid microbiology testing market is expected to reach US$6.2 Bln by 2022, expanding at CAGR of 7.3% from 2016 to 2022.
CHAIRED BY: James Drinkwater, Chairman, Pharmaceutical and Healthcare Sciences Society and Olivier Chancel, Sterility and Aseptic Process Assurance, Expert, Boehringer Ingelheim
SPEAKERS INCLUDE:
• Alexander Stoll, VP Competence Center Microbiology and Aseptic Technique Quality Management, Fresenius Kabi
• Di Morris, Senior Manager, Team Leader, Vaccines Quality Audit, GSK
• Philippe Dutot, Sterility Assurance Specialist, Novo Nordisk
• Thierry Bonnevay, Microbiology Platform Head, Analytical Research and Development, Sanofi Pasteur
• Tim Eaton, Sterile Manufacturing Specialist, AstraZeneca
KEY TOPICS:
- Rapid Microbial Methods
- Revision of Annex 1 and impact on pharmaceutical microbiology
- Contamination control strategies and case studies
- Mycoplasma detection, prevention and control
- Future of endotoxin testing in pharmaceutical industries
- Strengths and weaknesses of vaporized Hydrogen peroxide as a bio-contamination control agent
- Mold contamination control
- Influence of temperature of incubation on results of microbiological environmental monitoring
WHO SHOULD ATTEND
Senior Microbiologist, Lead Scientist, Lab Mgr, QA Specialist Drug Substance External Manufacturer, BD Mngr - Testing, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist
GOLD SPONSOR: DuPont
SPONSORS: Mettler Toledo, Biomerieux and Copan Group
